1. In Vivo
  2. >>Archive

INFUSE Review Leads To Discussion And Some Discord At NASS

Medtronic’s subdued showing at NASS in October revealed the sometimes rocky relationship among industry, clinicians, and academia:  The Yale University Open Data Access Project suggested rhBMP-2 didn’t fuse bone any better than standard-iliac crest bone graft, yet Medtronic executives found some vindication in the process, saying it supported on-label use of BMP, and suggested the Yale University-led process could be a model to settle future controversies in the medical industry.

Medtronic PLC’s exhibit at the North American Spine Society (NASS) 28th Annual Meeting in October was a gap in the otherwise toothy bright smile on the technical floor. The company chose to set up only a few modest tables, a couch, and a booth, providing a stark contrast to the other exhibits on the floor, but that was the point. Medtronic executives sent a message. They were disappointed with the tone of the conference’s discussions regarding recombinant human bone morphogenetic protein-2 (rhBMP-2), the key ingredient in Medtronic’s INFUSE bone graft. The company kept its sales people away from the booth, making only medical affairs personnel available to answer clinical question from doctors. (See Also see "Medtronic “Repurposes” Spine Convention Booth To Tell Its Side of BMP Story" - In Vivo, 14 October, 2013..)

Medtronic’s subdued showing revealed the sometimes rocky relationship among industry, clinicians, and academia. Just a few months earlier, Medtronic stood...

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Crisis Or Opportunity? US MFN Policy Could Test Japan’s Appetite For Reforms

 
• By Lisa Takagi

While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.

Rising Leaders 2025: Ovid’s Meg Alexander On Neurology’s Next Frontier

 
• By Jo Shorthouse

Ovid Therapeutics' president and COO Meg Alexander is leading the company’s strategic pivot toward innovative neurological treatments, potentially creating a new class of medicines for rare neurological disorders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By David Wild

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.